The Molecular Analysis for Personalised Therapy Congress 2019 programme is now available online!
Molecular Analysis for Personalised Therapy Congress 2019 is a meeting established by global opinion leaders, design to Interpreting Molecular Alterations for Clinical Practice and integrating insights from tumour samples analysis into daily practice.
MAP 2019 is a joint initiative of Cancer Research UK, UNICANCER and ESMO.
The meeting is highly recommended for medical oncologists, young professionals, PhDs, academics, regulators, industry R&D representatives and investigators and all those interested in the clinical interpretation of molecular tests to providing effective cancer treatment and deliver Precision Medicine.
MAP 2019 will be the place for networking with leading academic representatives working in Precision Medicine for cancer patients.
Drug development is a fast-moving field and most of the new drugs presently in development or recently approved are driven by molecular alterations. Understanding these molecular alterations, their mechanisms of action and how they can apply to therapy is a new challenge in medical oncology and clinical practice.
MAP 2019, 7-9 November 2019, London, UK, will be the place where the most recent data in Precision Medicine will presented and discussed.
- To identify molecular targets in various tumour types
- To understand new concepts (like Clonal Evolution) and technologies (like Single Cell analysis)
- To illustrate how new technologies (AI, Radiomics, Digital multiplex and Computational tools) can help predicting outcome
- To access new approaches in tumour immunology besides Immune Check-point Inhibitors
- To learn how to test and use at the best knowledge of technology predictive biomarkers
- To discuss the design of innovative trials for better outcome achievements
After attending MAP 2019, participants will be more knowledgeable in interpreting molecular alterations obtained from patient tumours thru appropriate testing and treatment decision to deliver precision medicine.
ESMO-MORA: The MAP 2019 programme has been accredited with 17 cat.1 ESMO-MORA points. Recertification is necessary for medical oncologists to remain professionally certified by ESMO. It also guarantees that a certified medical oncologist has continued to update her/his knowledge and still possess the necessary skills and standards for the practice of medical oncology. See here for further details.
The Congress webcasts will include all the sessions of the official programme, where Speaker permission is granted, and will be available on this website and OncologyPRO for ESMO members.